PBH Stock Forecast & Price Target

Prestige Consumer Healthcare demonstrates a robust growth trajectory, with forecasted revenues of $7,322 million representing a 13.2% increase. The company's adjusted EBITDA is projected to reach $690 million, reflecting a strong growth rate of 16.3%, along with an improvement in margins, expected to rise by 25 basis points to 9.4%. The company's ability to maintain a diverse portfolio of category-leading brands in the healthcare niche positions it favorably within the market, enhancing its long-term financial outlook.

Prestige Consumer Healthcare's adjusted EBITDA margins declined to 9.1%, reflecting a year-over-year decrease of 38 basis points, primarily due to raw material cost inflation and underperformance from recent acquisitions. The company's consolidated adjusted EBITDA margins further dipped to 8.1%, missing expectations by 15 basis points, highlighting ongoing margin compression. Additionally, the firm faces challenges in revenue growth and potential further multiple compression, creating a negative outlook on its financial performance.